Anzeige
Mehr »
Dienstag, 26.08.2025 - Börsentäglich über 12.000 News
Breaking: AlsetAI zündet nächste Stufe - Neue Allianz mit CHIP Datacentres & Hochkarätige Vorstände markieren Wendepunkt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AHDP | ISIN: CH0308403085 | Ticker-Symbol: GEM
Frankfurt
26.08.25 | 08:05
0,028 Euro
-25,00 % -0,009
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENEURO SA Chart 1 Jahr
5-Tage-Chart
GENEURO SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,0320,03320:53

Aktuelle News zur GENEURO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
GENEURO Aktie jetzt für 0€ handeln
16.07.GeNeuro SA Announces the Liquidation of Its French Subsidiary GeNeuro Innovation SAS227Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Lyon Economic...
► Artikel lesen
30.06.GeNeuro Announces Approval of All Resolutions Proposed at Extraordinary General Meeting29569.1% of the Company's share capital was represented at the EGM and resolutions were all unanimously approved Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical...
► Artikel lesen
12.06.GeNeuro SA Announces the Opening of Receivership Proceedings for Its French Subsidiary GeNeuro Innovation SAS368Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that, at the company's...
► Artikel lesen
10.06.GeNeuro SA Announces an Extraordinary Shareholders' Meeting on June 30, 2025328Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that it will hold an...
► Artikel lesen
27.05.GeNeuro SA Announces Definitive Debt-Restructuring Moratorium398Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
12.05.GeNeuro SA Announces the Postponement of the Publication of the Company's 2024 Annual Results445Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of...
► Artikel lesen
28.01.GeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium594Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
06.12.24New Data Supporting a New Precision Medicine Approach for ALS Patients With GeNeuro's GNK-301 Presented at the 35th International Symposium on ALS/MND910Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases...
► Artikel lesen
30.09.24GeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings623Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court...
► Artikel lesen
19.09.24GeNeuro: New Data Presented at the ECTRIMS 2025 Congress in Copenhagen Shows That Temelimab Rescues the Neurodegenerative Effects of HERV-W in an MS Model619Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases...
► Artikel lesen
28.08.24XFRA GEM: WIEDERAUFNAHME/RESUMPTION481FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1